Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. More Details
No risks detected for 4527 from our risk checks.
Excellent balance sheet and good value.
Share Price & News
How has Rohto PharmaceuticalLtd's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4527 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4527's weekly volatility (3%) has been stable over the past year.
7 Day Return
JP Personal Products
1 Year Return
JP Personal Products
Return vs Industry: 4527 underperformed the JP Personal Products industry which returned 12.1% over the past year.
Return vs Market: 4527 underperformed the JP Market which returned 27.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Rohto PharmaceuticalLtd's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Rohto PharmaceuticalLtd undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 4527 (¥2879) is trading below our estimate of fair value (¥3778.88)
Significantly Below Fair Value: 4527 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 4527 is good value based on its PE Ratio (19.6x) compared to the JP Personal Products industry average (35.7x).
PE vs Market: 4527 is poor value based on its PE Ratio (19.6x) compared to the JP market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: 4527 is poor value based on its PEG Ratio (3.5x)
Price to Book Ratio
PB vs Industry: 4527 is good value based on its PB Ratio (2.1x) compared to the JP Personal Products industry average (3.5x).
How is Rohto PharmaceuticalLtd forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4527's forecast earnings growth (5.6% per year) is above the savings rate (0%).
Earnings vs Market: 4527's earnings (5.6% per year) are forecast to grow slower than the JP market (12% per year).
High Growth Earnings: 4527's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4527's revenue (3.1% per year) is forecast to grow slower than the JP market (5.2% per year).
High Growth Revenue: 4527's revenue (3.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4527's Return on Equity is forecast to be low in 3 years time (10.1%).
How has Rohto PharmaceuticalLtd performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4527 has high quality earnings.
Growing Profit Margin: 4527's current net profit margins (9.2%) are higher than last year (8.2%).
Past Earnings Growth Analysis
Earnings Trend: 4527's earnings have grown by 10.4% per year over the past 5 years.
Accelerating Growth: 4527's earnings growth over the past year (8.7%) is below its 5-year average (10.4% per year).
Earnings vs Industry: 4527 earnings growth over the past year (8.7%) exceeded the Personal Products industry -18.7%.
Return on Equity
High ROE: 4527's Return on Equity (10.7%) is considered low.
How is Rohto PharmaceuticalLtd's financial position?
Financial Position Analysis
Short Term Liabilities: 4527's short term assets (¥133.1B) exceed its short term liabilities (¥56.5B).
Long Term Liabilities: 4527's short term assets (¥133.1B) exceed its long term liabilities (¥12.7B).
Debt to Equity History and Analysis
Debt Level: 4527's debt to equity ratio (5.2%) is considered satisfactory.
Reducing Debt: 4527's debt to equity ratio has increased from 4.9% to 5.2% over the past 5 years.
Debt Coverage: 4527's debt is well covered by operating cash flow (247%).
Interest Coverage: 4527 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Rohto PharmaceuticalLtd current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 4527's dividend (1.04%) isn’t notable compared to the bottom 25% of dividend payers in the JP market (1.33%).
High Dividend: 4527's dividend (1.04%) is low compared to the top 25% of dividend payers in the JP market (3%).
Stability and Growth of Payments
Stable Dividend: 4527's dividends per share have been stable in the past 10 years.
Growing Dividend: 4527's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (19.1%), 4527's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yamada Kunio (65 yo)
Mr. Yamada Kunio had been the President at Rohto Pharmaceutical Co. Ltd. since June 9, 2009 until 2019. Mr. Kunio has been the Chairman of the Board of Directors and Representative Director at Rohto Pharma...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Yamada's total compensation is reasonable compared to companies of similar size in the JP market.
Compensation vs Earnings: Yamada's compensation has been consistent with company performance over the past year.
Experienced Management: 4527's management team is considered experienced (2.5 years average tenure).
Experienced Board: 4527's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Rohto Pharmaceutical Co.,Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Rohto Pharmaceutical Co.,Ltd.
- Ticker: 4527
- Exchange: TSE
- Founded: 1899
- Industry: Personal Products
- Sector: Household
- Market Cap: JP¥336.279b
- Shares outstanding: 114.07m
- Website: https://www.rohto.co.jp
Number of Employees
- Rohto Pharmaceutical Co.,Ltd.
- 1-8-1, Tatsumi-nishi
Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company offers eye care products, such as eye drops, care for contact lenses, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/30 16:21|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.